Bullish indicating open at $55-$60, IPO prices at $37
CAMBRIDGE, Mass.—Jeffrey V. Poulton, Executive Vice President and Chief Financial Officer of Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), a $31.4 billion market cap company that has delivered a remarkable 61.7% return over the past year, recently reported a series of stock transactions, primarily involving the sale of company shares valued at approximately $192,389.
According to the latest SEC filing, Poulton executed multiple sales of Alnylam’s common stock on February 28, 2025. The shares were sold at prices ranging from $236.51 to $244.11 per share, within the company’s analyst target range of $195 to $500. These transactions were part of a mandatory sell-to-cover provision to address tax withholding obligations related to vested restricted stock units.
Earlier, on February 27, 2025, Poulton acquired 1,908 shares through the vesting of restricted stock units, with no cash outlay, as part of the company’s stock incentive plan. This acquisition increased his direct holdings to 34,694 shares before the subsequent sales.
Alnylam Pharmaceuticals, based in Cambridge, Massachusetts, is engaged in developing RNA interference therapeutics. The recent stock transactions by its CFO reflect routine financial management activities within the company.
In other recent news, Alnylam Pharmaceuticals has been the focus of several analyst updates and strategic developments. H.C. Wainwright raised its price target for Alnylam to $500, maintaining a Buy rating, highlighting the potential of AMVUTTRA and nucresiran in treating transthyretin-mediated diseases. Piper Sandler also expressed confidence in Alnylam, maintaining an Overweight rating and a $304 price target, with expectations of AMVUTTRA’s approval potentially boosting sales to $2.75 billion by 2026. Meanwhile, RBC Capital maintained its Outperform rating with a $310 target, pointing to Alnylam’s robust research and development pipeline and upcoming Prescription Drug User Fee Act (PDUFA) date.
Alnylam reported fourth-quarter earnings that aligned with previous estimates, projecting net product revenues between $2.05 billion and $2.25 billion for 2025. The company is preparing for the commercial launch of AMVUTTRA for ATTR-CM, with a PDUFA date set for March 23, 2025. Upcoming Phase 3 trials for nucresiran and zilebesiran are scheduled for 2025, with significant anticipation surrounding these developments. Additionally, Canaccord Genuity slightly increased its price target to $385, maintaining a Buy rating, and emphasized the potential label expansion of Amvuttra for ATTR-CM.
Alnylam’s R&D Day showcased its diverse pipeline, including new targets for obesity and type 2 diabetes, and emphasized its differentiated approach in the central nervous system therapeutic area. The company plans to file multiple Investigational New Drug applications throughout the year, aiming to have over 25 clinical programs in progress by the end of 2025. Analysts have shown optimism for Alnylam’s future prospects, with a focus on its strategic positioning in the RNAi therapeutics market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.